Adipocyte plasma membrane-associated protein (APMAP)

Adipocyte plasma membrane-associated protein (APMAP) is a multifunctional type II transmembrane glycoprotein widely expressed in adipose tissue, liver, brain, placenta, vasculature, and other tissues. It is structurally similar to paraoxonases, exhibits arylesterase activity, and localizes to both the endoplasmic reticulum and plasma membrane. APMAP is a key regulator of adipocyte differentiation and lipid metabolism, where its expression is induced by PPARγ during adipogenesis, facilitating cell maturation and lipid accumulation[1][3][4]. In the central nervous system, APMAP functions as a negative regulator of amyloid-β production through interaction with amyloid precursor protein (APP) and γ-secretase, with partial depletion leading to increased amyloidogenic processing and potential relevance to Alzheimer’s disease models[1]. In viral pathogenesis, APMAP acts as a host factor promoting infection by viruses such as human cytomegalovirus (HCMV) and JC polyomavirus by mediating viral entry and nuclear transport of viral proteins[1][5]. In oncology, high levels of APMAP are correlated with tumor aggressiveness, metastatic potential in several cancer types, and its glycosylation status is under investigation as a biomarker for metastasis[1]. Although APMAP is a promising modulator in a variety of disease contexts, no known therapeutic drugs currently target APMAP directly. Its manipulation may have pleiotropic effects due to its involvement in essential cell differentiation, metabolic, neurodegenerative, and infection pathways[1][3][5][6].

Other names

C20orf3BSCvChromosome 20 open reading frame 3Protein BSCv

PPARγ agonists ↑ APMAP expression, promoting adipocyte differentiation No direct-acting small molecules or biologics for APMAP described in curated drug interaction databases